New Zealand markets closed

Madrigal Pharmaceuticals, Inc. (MDGL)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
220.06+2.89 (+1.33%)
At close: 04:00PM EDT
220.06 0.00 (0.00%)
After hours: 04:02PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 4.69B
Enterprise value 3.75B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)5.51
Enterprise value/revenue N/A
Enterprise value/EBITDA -8.32

Trading information

Stock price history

Beta (5Y monthly) -0.34
52-week change 3-22.92%
S&P500 52-week change 326.49%
52-week high 3302.68
52-week low 3119.76
50-day moving average 3234.20
200-day moving average 3201.76

Share statistics

Avg vol (3-month) 3517.18k
Avg vol (10-day) 3388.45k
Shares outstanding 521.31M
Implied shares outstanding 621.31M
Float 812.29M
% held by insiders 115.35%
% held by institutions 199.81%
Shares short (30 Apr 2024) 43.98M
Short ratio (30 Apr 2024) 49.74
Short % of float (30 Apr 2024) 427.13%
Short % of shares outstanding (30 Apr 2024) 418.70%
Shares short (prior month 28 Mar 2024) 43.36M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 325 Jul 2016
Ex-dividend date 4N/A
Last split factor 21:35
Last split date 325 Jul 2016

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-40.13%
Return on equity (ttm)-88.78%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -453.63M
Net income avi to common (ttm)-444.28M
Diluted EPS (ttm)-23.15
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.06B
Total cash per share (mrq)49.69
Total debt (mrq)117.72M
Total debt/equity (mrq)13.84%
Current ratio (mrq)9.39
Book value per share (mrq)41.13

Cash flow statement

Operating cash flow (ttm)-389.32M
Levered free cash flow (ttm)-229.94M